Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25586596 | 0.84 | TSHR (0.60) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL10359289 | 0.84 | TSHR (0.65) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL25974456 | 0.83 | HTR2A (0.46) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL900982 | 0.82 | TSHR (0.57) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL12817393 | 0.81 | TSHR (0.57) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL7172382 | 0.81 | CSNK2A1 (0.59) | TSHRSMN1; SMN2MAPTLMNAALOX12 | |
| SCHEMBL12830571 | 0.80 | TSHR (0.59) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL21056082 | 0.80 | TSHR (0.55) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL21056083 | 0.80 | TSHR (0.55) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL8280908 | 0.78 | FFAR4 (0.43) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023168484-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023092188-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-06-01 | — | — | WO | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| CN-101501061-A | Macrocyclic compounds as antiviral agents | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-08-05 | — | — | CN | disclosed |
| CN-101263156-A | Novel macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE INC (US) | 2008-09-10 | — | — | CN | disclosed |
| CN-101233148-A | Macrocyclic peptides as HCV NS3 protease inhibitors | MERCK & CO INC (US) | 2008-07-30 | — | — | CN | disclosed |
| EP-0257374-A1 | Phenoxybenzoic-acid derivatives | BAYER AG (DE) | 1988-03-02 | — | — | EP | disclosed |
| EP-0247486-A1 | Oxabicyclo[2.2.1]heptene derivatives | BAYER AG (DE) | 1987-12-02 | — | — | EP | disclosed |
| EP-0220635-A1 | Phenoxybenzoic-acid derivatives | BAYER AG (DE) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | TSHR 2846/4885HTR2A 1889/4885HTR2C 3002/4885 |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | TSHR 3065/4885HTR2A 2115/4885HTR2C 3428/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | TSHR 3070/4885HTR2A 3874/4885HTR2C 4288/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | TSHR 3471/4885HTR2A 1522/4885HTR2C 2884/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | TSHR 3727/4885HTR2A 2979/4885HTR2C 3389/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | TSHR 2455/4885HTR2A 2000/4885HTR2C 3033/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | TSHR 3610/4885HTR2A 2888/4885HTR2C 3397/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | TSHR 2455/4885HTR2A 2000/4885HTR2C 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.